Cerulean Pharma Inc., a Cambridge company developing tumor-targeted nanopharmaceuticals, today said it has dosed the first patients in a Phase 2 clinical trial of its main drug candidate CRLX101, a potential therapy for non-small cell lung cancer (NSCLC).
The primary goal of the study is to assess the efficacy and safety of CRLX101 in advanced NSCLC patients whose disease has progressed after one or two prior regimens of therapy. About 150 patients will be enrolled in the study at 26 trial sites in Russia and Ukraine. Patients will be randomized to receive either CRLX101 plus best supportive care or best supportive care, respectively. They will be evaluated for overall survival, progression-free survival, tumor response, and pharmacokinetic parameters